Arcellx, Inc.

NasdaqGS:ACLX Stock Report

Market Cap: US$5.1b

Arcellx Valuation

Is ACLX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ACLX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

US$556.06
Fair Value
84.0% undervalued intrinsic discount
17
Number of Analysts

Below Fair Value: ACLX ($88.85) is trading below our estimate of fair value ($556.06)

Significantly Below Fair Value: ACLX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ACLX?

Key metric: As ACLX barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ACLX. This is calculated by dividing ACLX's market cap by their current book value.
What is ACLX's PB Ratio?
PB Ratio12.6x
BookUS$392.22m
Market CapUS$5.12b

Price to Book Ratio vs Peers

How does ACLX's PB Ratio compare to its peers?

The above table shows the PB ratio for ACLX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average11.5x
MIRM Mirum Pharmaceuticals
14.7x68.33%US$3.8b
LEGN Legend Biotech
5.8x62.31%US$6.2b
PTGX Protagonist Therapeutics
7.1x37.94%US$4.8b
TGTX TG Therapeutics
18.4x38.35%US$5.1b
ACLX Arcellx
12.6x53.36%US$5.1b

Price-To-Book vs Peers: ACLX is expensive based on its Price-To-Book Ratio (12.6x) compared to the peer average (11.5x).

Price to Book Ratio vs Industry

How does ACLX's PB Ratio compare vs other companies in the US Biotechs Industry?

54 CompaniesPrice / BookEstimated GrowthMarket Cap
NKTX Nkarta
0.5x1.69%US$186.79m
ZNTL Zentalis Pharmaceuticals
0.4x13.87%US$114.70m
XBIT XBiotech
0.4xn/aUS$77.44m
ARTV Artiva Biotherapeutics
0.5x-9.92%US$73.52m
ACLX 12.6xIndustry Avg. 2.6xNo. of Companies72PB0246810+
54 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ACLX is expensive based on its Price-To-Book Ratio (12.6x) compared to the US Biotechs industry average (2.6x).

Price to Book Ratio vs Fair Ratio

What is ACLX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ACLX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio12.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ACLX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ACLX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$88.85
US$112.53
+26.65%
9.21%US$134.00US$88.00n/a17
Oct ’26US$82.03
US$113.07
+37.84%
7.03%US$134.00US$100.00n/a15
Sep ’26US$69.39
US$113.07
+62.94%
7.03%US$134.00US$100.00n/a15
Aug ’26US$71.14
US$113.80
+59.97%
8.16%US$134.00US$100.00n/a15
Jul ’26US$64.69
US$111.13
+71.79%
8.21%US$134.00US$93.00n/a15
Jun ’26US$62.06
US$111.53
+79.72%
8.65%US$134.00US$93.00n/a15
May ’26US$65.53
US$115.40
+76.10%
7.68%US$134.00US$104.00n/a15
Apr ’26US$60.70
US$115.40
+90.12%
7.68%US$134.00US$104.00n/a15
Mar ’26US$64.82
US$116.13
+79.15%
7.10%US$134.00US$104.00n/a16
Feb ’26US$68.13
US$116.38
+70.81%
7.18%US$134.00US$104.00n/a16
Jan ’26US$76.69
US$116.38
+51.75%
7.18%US$134.00US$104.00n/a16
Dec ’25US$88.07
US$114.44
+29.94%
9.07%US$134.00US$95.00n/a16
Nov ’25US$86.17
US$95.56
+10.90%
16.63%US$122.00US$73.00n/a16
Oct ’25US$81.44
US$83.71
+2.79%
9.03%US$106.00US$73.00US$82.0314
Sep ’25US$68.74
US$79.87
+16.19%
5.80%US$87.00US$70.00US$69.3915
Aug ’25US$58.65
US$79.93
+36.29%
5.75%US$87.00US$70.00US$71.1415
Jul ’25US$53.60
US$79.93
+49.13%
5.75%US$87.00US$70.00US$64.6915
Jun ’25US$52.00
US$79.93
+53.72%
5.75%US$87.00US$70.00US$62.0615
May ’25US$52.18
US$80.31
+53.91%
4.82%US$87.00US$73.00US$65.5313
Apr ’25US$66.98
US$80.31
+19.90%
4.82%US$87.00US$73.00US$60.7013
Mar ’25US$66.82
US$75.92
+13.61%
9.43%US$85.00US$57.00US$64.8212
Feb ’25US$63.82
US$65.50
+2.63%
9.32%US$79.00US$57.00US$68.1312
Jan ’25US$55.50
US$65.00
+17.12%
9.04%US$79.00US$57.00US$76.6912
Dec ’24US$54.98
US$60.09
+9.30%
9.74%US$70.00US$49.00US$88.0711
Nov ’24US$34.39
US$51.64
+50.15%
5.91%US$58.00US$48.00US$86.1711
Oct ’24US$35.88
US$50.70
+41.30%
9.66%US$58.00US$39.00US$81.4410
US$112.53
Fair Value
21.0% undervalued intrinsic discount
17
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/16 18:04
End of Day Share Price 2025/10/16 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Arcellx, Inc. is covered by 26 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Carter GouldBarclays
Peter LawsonBarclays